Role of serum HER2 (sHER2) levels to predict acquisition of HER2 overexpression in patients with metastatic lesions of breast cancer with HER2-negative/unknown at the primary site

被引：1
|
作者：
Ribeiro, J. T. M. L.
Ali, S. M.
Correia, L.
Luis, I. M. V. D.
Matias, M.
Amaral, T.
Quintela, A. A. F. G.
Leitzel, K.
Lipton, A.
Costa, L.
机构：
[1] Hosp Santa Maria, Dept Oncol, Lisbon, Portugal
[2] Univ Lisbon, Inst Mol Med, P-1699 Lisbon, Portugal
[3] Lebanon VA Med Ctr, Penn State Hershey Med Ctr, Hershey, PA USA
[4] Hosp Santa Maria, Dept Pathol, Lisbon, Portugal
[5] Penn State Hershey Med Ctr, Hershey, PA USA
[6] Hosp Santa Maria, Dept Oncol, CHLN, Lisbon, Portugal
[7] IMM, Clin & Translat Oncol Res Unit, Lisbon, Portugal
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e11114
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11114
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Reassessment of HER2 status in breast cancer patients at the time of metastatic disease by serum HER2 and HER2 status of circulating tumor cells
    Fehm, Tania
    TUMOR BIOLOGY, 2007, 28 : 22 - 22
  • [22] Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer
    Aurilio, Gaetano
    Sandri, Maria Teresa
    Pruneri, Giancarlo
    Zorzino, Laura
    Botteri, Edoardo
    Munzone, Elisabetta
    Adamoli, Laura
    Facchi, Giuseppina
    Cullura, Daniela
    Verri, Elena
    Rocca, Maria Cossu
    Zurrida, Stefano
    Iacovelli, Roberto
    Nole, Franco
    FUTURE ONCOLOGY, 2016, 12 (17) : 2001 - 2008
  • [23] Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
    Horimoto, Yoshiya
    Ishizuka, Yumiko
    Ueki, Yuko
    Higuchi, Toru
    Arakawa, Atsushi
    Saito, Mitsue
    BMC CANCER, 2022, 22 (01)
  • [24] Comparison between HER2 extracellular domain in serum and HER2 overexpression in breast cancer tissue
    Zidan, J.
    Mzalbat, R.
    Svalb, S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S142 - S142
  • [25] Comparison between HER2 extracellular domain in serum and HER2 overexpression in breast cancer tissue
    Zidan, J.
    Mzalbat, R.
    Shnaider, J.
    Sharabi, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [26] Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
    Yoshiya Horimoto
    Yumiko Ishizuka
    Yuko Ueki
    Toru Higuchi
    Atsushi Arakawa
    Mitsue Saito
    BMC Cancer, 22
  • [27] ELEVATED SERUM LEVELS OF THE HER2 EXTRACELLULAR DOMAIN (ECD) IN PRIMARY BREAST CANCER (PBC) WITH HER2 OVEREXPRESSION PREDICT EARLY FAILURE OF ADJUVANT TRASTUZUMAB
    Thureau, S.
    Clatot, F.
    Laberge-Le-Couteulx, S.
    Baron, M.
    Basuyau, J. P.
    Blot, E.
    ANNALS OF ONCOLOGY, 2010, 21 : 82 - 82
  • [28] HER2 exon 27 mutations predict worse survival of breast cancer patients, especially in HER2-negative patients
    Si, Pilei
    Chen, Tao
    Fang, Bin
    Yao, Jiabing
    Liu, Gaoxiu
    Chen, Haijun
    Zhai, Baoping
    Li, Wentao
    CANCER MEDICINE, 2017, 6 (12): : 2832 - 2839
  • [29] Evaluation of analytical accuracy of HER2 status in patients with breast cancer Comparison of HER2 GPA with HER2 IHC and HER2 FISH
    Jensen, Steffen Grann
    Thomas, Peter Engel
    Christensen, Ib Jarle
    Balslev, Eva
    Hansen, Alastair
    Hogdall, Estrid
    APMIS, 2020, 128 (11) : 573 - 582
  • [30] Radiolabeled trastuzumab biodistribution and serum HER2 levels in HER2-positive metastatic breast cancer patients
    Perik, Patrick J.
    Lub-de Hogge, Marjolijn N.
    Gietema, Jourik A.
    Jager, Piet L.
    Kosterink, Jos G.
    de Korte, Sander A.
    van Veldhuisen, Drik J.
    van der Graaf, Winette T.
    Sieijfer, Drik T.
    de Vries, Elisabeth G.
    ANNALS OF ONCOLOGY, 2004, 15 : 14 - 14
12345